Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc. is a clinical-stage biotechnology company headquartered in Shanghai, China. The company is focused on the discovery, development, and commercialization of antibody-drug conjugates (ADCs) and other innovative biologic therapies, primarily for oncology indications, with additional programs in immunology. Duality Biologics has built a pipeline of next-generation ADC candidates designed to improve the therapeutic index and overcome resistance mechanisms associated with earlier generations of ADC therapies. The company operates in the highly competitive global ADC space, where it competes with both established pharmaceutical companies and emerging biotechs. Duality has pursued a strategy of developing differentiated ADC platforms and has entered into licensing and collaboration agreements with multinational pharmaceutical partners to advance its candidates into global clinical trials. These partnerships are a key part of its business model, providing both validation and non-dilutive funding. Duality Biotherapeutics is privately held and has attracted investment from venture capital and strategic investors. Its headquarters in Shanghai places it within China's rapidly growing biotech ecosystem, which has become a major source of ADC innovation. The company's website is dualitybiologics.com. As a clinical-stage company, Duality's near-term value is driven by clinical trial readouts, regulatory milestones, and the progress of its partnered programs. It does not yet market any approved products.

Duality Biotherapeutics, Inc. is a biotechnology company based in Shanghai, China. It was founded in 2019 and has since focused on the development of antibody-drug conjugates (ADCs) and other biologic therapies. The company is part of a wave of Chinese biotechs that have gained prominence in the global ADC field. Duality has advanced multiple ADC candidates into clinical development and has established collaborations with international pharmaceutical companies. These partnerships typically involve licensing rights to develop and commercialize Duality's ADC candidates in markets outside China, while Duality retains rights in China or receives royalties and milestone payments. Such deals have provided the company with capital and external validation of its technology platforms. The company remains privately held and is backed by venture capital and strategic investors. Its headquarters in Shanghai positions it within one of the world's fastest-growing biotech hubs. As of the available evidence, Duality Biotherapeutics is an active clinical-stage company with no approved products on the market.

• 2019

  Duality Biotherapeutics founded in Shanghai, China.

Clinical-stage biotech focused on differentiated antibody-drug conjugates for oncology and immunology.

• ADC pipeline

  Clinical-stage antibody-drug conjugate candidates for oncology and immunology.

• 2021.05.20

  Reported2021.05.20

  Duality Biologics completes $90 million Series B financing[2]映恩生物完成9000万美元B轮融资prnasia.com

  Duality Biologics announced that it had completed a $90 million Series B financing led by Lilly Asia Ventures, with other funds participating. The proceeds are primarily intended to support preclinical research, clinical development and product licensing across the company’s pipeline.

Read more

1. 1Duality Biotherapeutics, Inc. (China) - Wikidatawikidata.org
2. 2映恩生物完成9000万美元B轮融资prnasia.com